On Friday, ImmunityBio Inc (NASDAQ: IBRX) opened higher 1.46% from the last session, before settling in for the closing price of $2.4. Price fluctuations for IBRX have ranged from $1.83 to $7.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 2.39%. Company’s average yearly earnings per share was noted 21.29% at the time writing. With a float of $98.33 million, this company’s outstanding shares have now reached $915.63 million.
Let’s determine the extent of company efficiency that accounts for 680 employees. In terms of profitability, gross margin is 99.66%, operating margin of -504.18%, and the pretax margin is -648.2%.
ImmunityBio Inc (IBRX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ImmunityBio Inc is 89.60%, while institutional ownership is 8.79%.
ImmunityBio Inc (IBRX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.12 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.18) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 59.89% during the next five years compared to 2.39% growth over the previous five years of trading.
ImmunityBio Inc (NASDAQ: IBRX) Trading Performance Indicators
Check out the current performance indicators for ImmunityBio Inc (IBRX). In the past quarter, the stock posted a quick ratio of 3.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 40.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.49, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of ImmunityBio Inc (IBRX)
Looking closely at ImmunityBio Inc (NASDAQ: IBRX), its last 5-days average volume was 5.9 million, which is a drop from its year-to-date volume of 7.66 million. As of the previous 9 days, the stock’s Stochastic %D was 17.14%.
During the past 100 days, ImmunityBio Inc’s (IBRX) raw stochastic average was set at 31.61%, which indicates a significant increase from 14.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.15 in the past 14 days, which was lower than the 0.21 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.77, while its 200-day Moving Average is $3.20.
